written on 24.06.2014
Tags:
,

Struggling Endo grabs generics maker DAVA for up to $600M

TAGS: ,

Endo, in a world of financial hurt, has been turning to M&A lately to ease the pain. Its latest move: a deal for New Jersey generics maker DAVA Pharmaceuticals worth up to $600 million.

Latest Report